^
2d
G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Massachusetts General Hospital | N=40 --> 60
Enrollment change
|
temozolomide • Neupogen (filgrastim)
5d
G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
P2, N=40, Not yet recruiting, Massachusetts General Hospital | N=60 --> 40
Enrollment change
|
temozolomide • Neupogen (filgrastim)
14d
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (clinicaltrials.gov)
P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=24 --> 0 | Trial completion date: Dec 2029 --> Nov 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2029 --> Nov 2024
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
CD4 (CD4 Molecule)
|
paclitaxel • Neupogen (filgrastim)
18d
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov)
P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date
|
carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • Neupogen (filgrastim) • dexrazoxane
25d
Trial completion date
|
cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • mesna • Neupogen (filgrastim)
1m
Trial completion date
|
cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa • Neupogen (filgrastim)
1m
G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Massachusetts General Hospital
New P2 trial
|
temozolomide • Neupogen (filgrastim)
1m
RAFA: HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (clinicaltrials.gov)
P2, N=70, Recruiting, Children's Hospital Medical Center, Cincinnati | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2025
Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
1m
Enrollment closed • Enrollment change
|
Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
1m
SGN35-027: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=255, Terminated, Seagen Inc. | Trial completion date: Jun 2026 --> Aug 2024 | Active, not recruiting --> Terminated; The study was prematurely discontinued as the sponsor believes the data collected is enough to show the safety and efficacy of the combinations studied in all cohorts. The decision was not based on any safety and/or efficacy concerns.
Trial completion date • Trial termination
|
Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
2ms
Comparison of the efficacy of a generic plerixafor versus Mozobil as adjunct peripheral blood stem cell mobilization agents in multiple myeloma patients. (PubMed, Transfusion)
The generic plerixafor produced comparable cumulative collection yields and early engraftment outcomes as Mozobil, but fewer doses and collection days were needed to reach collection goal.
Journal
|
CD34 (CD34 molecule)
|
Neupogen (filgrastim) • plerixafor
2ms
Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF (clinicaltrials.gov)
P=N/A, N=100, Completed, Cairo University | Recruiting --> Completed | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Aug 2024
Trial completion • Trial completion date • Trial primary completion date
|
Neupogen (filgrastim)
2ms
NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
FLT3 positive
|
sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
2ms
Continuous Versus Bolus Administration of G-CSF in Children With Cancer (clinicaltrials.gov)
P4, N=20, Active, not recruiting, Chang Gung Memorial Hospital | Recruiting --> Active, not recruiting | N=40 --> 20
Enrollment closed • Enrollment change
|
Granocyte (lenograstim) • Neupogen (filgrastim)
2ms
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
P2, N=270, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
cytarabine • decitabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
2ms
New P2 trial
|
clonoSEQ
|
doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
2ms
Trial completion date • Combination therapy
|
gemcitabine • cyclophosphamide • prexasertib (ACR-368) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
3ms
Enrollment open
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 translocation
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
3ms
Haploidentical HCT for Severe Aplastic Anemia (clinicaltrials.gov)
P2, N=21, Recruiting, St. Jude Children's Research Hospital | Active, not recruiting --> Recruiting
Enrollment open
|
cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim)
3ms
Off-the-shelf NK Cells + SCT for Myeloid Malignancies (clinicaltrials.gov)
P1/2, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • DEK (DEK Proto-Oncogene)
|
cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
3ms
DEPEND: De-Escalation Therapy for Human Papillomavirus Negative Disease (clinicaltrials.gov)
P2, N=36, Recruiting, University of Chicago | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
Trial completion date • Trial primary completion date • Metastases
|
TMB (Tumor Mutational Burden)
|
Opdivo (nivolumab) • cisplatin • carboplatin • paclitaxel • 5-fluorouracil • hydroxyurea • Neupogen (filgrastim)
3ms
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=0, Withdrawn, Medical College of Wisconsin | N=36 --> 0 | Initiation date: May 2024 --> Aug 2024 | Not yet recruiting --> Withdrawn
Enrollment change • Trial initiation date • Trial withdrawal
|
Venclexta (venetoclax) • cytarabine • navitoclax (ABT 263) • mitoxantrone • Neupogen (filgrastim)
3ms
CRAFT: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (clinicaltrials.gov)
P2, N=52, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
carboplatin • Rozlytrek (entrectinib) • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
4ms
Enrollment change
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
4ms
ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
Trial completion date • Trial primary completion date • Viral vector
|
CD34 (CD34 molecule)
|
busulfan • Neupogen (filgrastim)
4ms
Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
4ms
Cisplatin-induced bone marrow failure in an adult patient with Fanconi anemia. (PubMed, J Oncol Pharm Pract)
SCC of the head and neck or gynecologic organs in a young adult without known risk factors should prompt consideration of FA. Cisplatin should be avoided in patients with FA.
Journal
|
FANCI (FA Complementation Group I)
|
cisplatin • Promacta (eltrombopag) • Neupogen (filgrastim)
4ms
New P2 trial
|
carboplatin • Rozlytrek (entrectinib) • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
4ms
Enrollment closed • Enrollment change
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
4ms
Combination therapy • Enrollment closed • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • CSF1R (Colony stimulating factor 1 receptor)
|
TruSight RNA Pan-Cancer Panel
|
imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • dexrazoxane
4ms
NCI-2018-00906: Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation (clinicaltrials.gov)
P1/2, N=62, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
Trial completion • Trial completion date • Trial primary completion date
|
Neupogen (filgrastim) • captisol-enabled melphalan
4ms
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov)
P2, N=16, Recruiting, Leland Metheny | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • carmustine • Neupogen (filgrastim)
4ms
Enrollment open
|
cyclophosphamide • carfilzomib • melphalan • Neupogen (filgrastim) • dexamethasone injection
4ms
New trial
|
Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Neupogen (filgrastim)
4ms
Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov)
P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
Enrollment closed
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
4ms
Trial completion
|
cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
4ms
Trial completion • Trial completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • busulfan • Neupogen (filgrastim)
4ms
Trial primary completion date
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
5ms
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
P2, N=17, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
Enrollment closed • Surgery
|
Keytruda (pembrolizumab) • cisplatin • doxorubicin hydrochloride • methotrexate • daunorubicin • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • methotrexate IV
5ms
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia (clinicaltrials.gov)
P2, N=33, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=20 --> 33 | Trial primary completion date: Dec 2025 --> Jun 2024
Enrollment closed • Enrollment change • Trial primary completion date
|
KMT2A (Lysine Methyltransferase 2A)
|
melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim)
5ms
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders (clinicaltrials.gov)
P=N/A, N=10, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
Trial completion • Metastases
|
KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim)
5ms
Trial suspension
|
cyclophosphamide • carfilzomib • melphalan • Neupogen (filgrastim) • dexamethasone injection